On Thursday, MannKind Corporation (NASDAQ:MNKD)’s shares declined -6.33% to $4.29.
MannKind Corporation (MNKD) will release its 2015 first quarter financial results on Thursday, May 7, 2015 and its administration will host a conference call to talk about the first quarter financial results and other Company developments at 9:00 AM (Eastern Time) on May 8, 2015.
MannKind Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic products for diabetes in the United States.
Varian Medical Systems, Inc. (NYSE:VAR)’s shares dropped -6.30% to $88.85.
Varian Medical Systems, Inc. (VAR) and Sarah Cannon, the global cancer enterprise of Hospital Corporation of America (HCA), recently declared a new initiative to upgrade the radiation oncology equipment across the Sarah Cannon Cancer Network of Excellence with newly advanced technology for image-guided, high-precision radiotherapy and radiosurgery. Sarah Cannon will also deploy Varian’s new InSightive™ software for data analytics and RapidPlan™ knowledge-based treatment planning software together with Varian’s ARIA® information administration and Eclipse™ treatment planning software. The software will support Sarah Cannon’s programs for using data to develop personalized treatment plans, improve outcomes, and expand clinical trial options for patients.
Varian Medical Systems, Inc. designs, manufactures, sells, and services medical devices and software products for treating cancer and other medical conditions in the United States. The company operates in two segments, Oncology Systems and Imaging Components.
At the end of Thursday’s trade, Stratasys, Ltd. (NASDAQ:SSYS)‘s shares dipped -6.21% to $37.45.
Stratasys, Ltd. (SSYS) announced preliminary first quarter 2015 results as well as updated 2015 financial guidance. The Company expects to report first quarter revenue in the range of $171 to $173 million; these results reflect negative impact of a stronger U.S. dollar in the amount of approximately $8.7 million when compared to foreign currency exchange rates last year. This represents an increase of approximately 14% over revenues for the first quarter of 2014, or 20% on a constant currency basis.
Stratasys Ltd. provides additive manufacturing (AM) solutions for the creation of parts used in the processes of designing and manufacturing products; and for the direct manufacture of end parts. Its AM systems utilize its patented fused deposition modeling and inkjet-based PolyJet technologies to enable the production of prototypes, tools used for production and manufactured goods directly from three-dimensional (3D) CAD files or other 3D content.
Exelixis, Inc. (NASDAQ:EXEL), ended its Thursday’s trading session with -6.20% loss, and closed at $2.57.
Exelixis, Inc. (EXEL) declared that the Exelixis-discovered compounds cabozantinib and cobimetinib will be the subjects of fourteen presentations at the forthcoming 2015 Annual Meeting of the American Society of Clinical Oncology (ASCO). The meeting, which will be held from May 29 to June 2, 2015 in Chicago, Illinois, is predictable to draw 30,000 oncology professionals from around the world.
Exelixis, Inc., a biopharmaceutical company, develops and sells small molecule therapies for the treatment of cancer in the United States. The company offers COMETRIQ, an inhibitor of multiple receptor tyrosine kinases for the treatment of patients with progressive, metastatic medullary thyroid cancer.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
